- Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study. Sulkowski, M., Reindollar, R., Thomas, D.L., Brinkley-Laughton, S., Hudson, M., Yu, J. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. (2002)